Jul 16, 2025 / 12:00PM GMT
Guido Oelkers - Swedish Orphan Biovitrum AB(publ)-Chief Executive Officer
Hello everybody. This is Guido Ercas, CEO of Sobi.
We are delighted to welcome you to the 2nd quarter 2025 conference call for investors and analysts. We posted this presentation to Sobi.com earlier.
Forward-looking statement as per usual, please take note of this.
And with this, let's go right into the next slide today we plan to cover key aspects of our Q2 report. I'm joined by Henrik Stenquist, our CFO, and Lidia Abaran, head of R&D and Chief Medical Officer. We plan to review the presentation first.
And then have a Q&A until until around 3 p.m. CT.
For those on the phone, please join the queue and for questions, as mentioned, please press 1.
And we ask you to only really request only to ask one maximum 2 questions at a time. Let's go to slide number 4.
The 2nd quarter when you elevate yourself was really for us about, strong economics, drive important pipeline milestones and create economic preconditions to support our
Q2 2025 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
3 days ago
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers